DOCSLIB.ORG

2006-2007 Annual Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2006-2007 Annual Report 2007 annual report 1 April 06 - 31 March 07 the future is in our genes. Chairman’s Message 02 President’s Message 04 OGI’s Mission 06 Research Programs Genetic Basis of Human Health 08 Biomarkers 12 Infectious Diseases and Promoting Global Health 14 Biodiversity, the Environment and Looking Ahead 16 Research Programs 18 Business Development Investments 20 Science - Industry Workshops 22 Outreach Public Outreach and Next Generation Innovators 24 Reaching Out Through The Arts 26 Workshops and Talks 28 Operations Board of Directors and Staff 29 Financial Snapshot 30 Financial Statements (inserted into flap at back) Copyright 2007 Ontario Genomics Institute 2007 annual report • 01 Chairman’s Message As Chair of the Ontario Genomics Institute (OGI), I am teomics research and to the growing cadre of internation- proud to report that the past year was for OGI a very posi- ally-recognized scientific researchers in this province whose tive reflection of our goal of augmenting -- through our knowledge and technical prowess are driving leading-edge focus on the genomics sector -- Ontario’s role as a pre- genomics research that will, in the long run, benefit all eminent centre in the life sciences industry. Now entering Canadians and help sustain and improve us economically. its seventh year, OGI continues to realize the benefits of sound strategic thinking, a clear direction, broad and fruit- Other partnerships have also been crucial. As always, the ful strategic partnerships, excellent recruitment and the partnerships with the various universities, research hospitals strong support of its major stakeholders. and other life science research institutions in Ontario (and beyond) has been of paramount importance. During this The commitment and support we are receiving from past year, 23 institutions from Ontario, six other provinces, Genome Canada and Ontario’s Ministry of Research and and 19 countries other than Canada were engaged as Innovation (MRI) provide the foundation of our present research collaborators on OGI-funded projects. and future success. Their collaborative and individual efforts have demonstrated their dedication to genomics and pro- In addition to funding from Genome Canada and Ontario’s 02 The commitment and support we are receiving from Genome Canada and Ontario’s Ministry of Research and Innovation (MRI) provide the foundation of our present and future success. MRI, co-funding (direct or in kind) for OGI-funded projects organize a workshop exploring the use of biomarkers in came from 106 other research institutions, philanthropic clinical trial design – CHI’s first-ever meeting hosted in foundations, public funding sources and commercial life Canada. The workshop attracted almost 100 participants science entities. Seventy-eight of these funding sources from 27 biotechnology and pharmaceutical companies from came from outside Ontario, including other provinces and Canada, France, Germany, Israel and the USA; more than 12 other countries. half the participants were from outside Canada, and had the opportunity, either to hear talks by several OGI-funded We have also had many day-to-day interactions and sev- speakers on the agenda, or to meet Ontario scientists at the eral focused collaborations with the various components of workshop-associated networking events. the Ontario Commercialization Network, including MaRS and the Research Innovation Network. Our partnership I want to thank Christian Burks, President and CEO, as well with the University of Toronto’s Joint Centre for Bioethics as OGI’s staff for their hard work in building and deepen- on topics related to the social impact of genomics research ing OGI’s role in the life sciences sector. I would also like to practice and outcomes continues to be very fruitful as well. thank OGI’s Board of Directors, and especially to express my deep appreciation to Joseph Rotman, who has retired We have continued to identify and cultivate strategic op- from the Board. He was instrumental as part of a core portunities and priorities that will help Ontario grow in the group of directors guiding OGI during its infancy and he knowledge-based innovation economy. Over the past year, helped lay the groundwork for OGI’s success. I would also five new start-up life science companies have grown out of like to thank Cheryl Reicin, who departed from the Board, OGI-funded projects. Previously established companies that for the perspective she brought from her practice at Tory’s. we have assisted are being acknowledged on the global stage. For example, Amorfix Life Sciences – in which we At the same time, I wish to welcome to the Board Elizabeth invested seed commercialization funds in FY2006 -- raised Dowdeswell, (Visiting Professor in Public Health Sciences, $20 million in new private and public funds for advanc- McLaughlin-Rotman Center for Global Health); Jay Lefton ing the extension of their technology to permit diagnosis (Partner, Ogilvy Renault); Bonnie Schmidt (President, Let’s of several neurodegenerative diseases. It was also the Talk Science); Tim McTiernan (Executive Director of Inno- only Canadian company among 47 companies worldwide vations and Assistant Vice-President, Research, University recognized as a Technology Pioneer by the World Economic of Toronto); and ex officio member, Alastair Glass (Deputy Forum in Davos earlier this year. Minister, Ontario MRI). We’ve also continued to partner with the commercial sector I look forward to another rewarding year and am encour- in sponsoring meetings that explore the interface between aged by the continued success I foresee in OGI’s future and the fruits of research and the marketplace. For example, the impact of large-scale genomics projects on Ontario’s life GE Healthcare and OGI organized and hosted a workshop sciences sector. at MaRS that explored the use of molecular imaging in tracking biomarkers in a science-industry workshop and were delighted to have participation of 24 companies involved in commercializing those technologies. OGI also partnered with Cambridge Healthtech Institute (CHI) to J. Mark Lievonen Chairman 2007 annual report • 03 President’s Message I am pleased to present the FY2007 Annual Report of the unidentified species). OGI-funded projects also contributed Ontario Genomics Institute (OGI). more than 55,000 depositions to major public data banks, including the Protein Data Bank (PDB) and newer data This is my third annual report at OGI, and it provides a banks tracking emerging data sets such as The Database of superb vantage point from which to appreciate the consid- Genomic Variation. erable momentum built up by the genomics and proteom- ics sector in Ontario, and by OGI in its primary mission of The Centre for Applied Genomics (TCAG), the Genome providing leadership in building a globally-competitive life Canada and OGI-funded genomics service platform, con- sciences industry in Ontario by creating leverageable ge- tinues to expand its user base and access to leading-edge nomics and proteomics resources with leading-edge science. and enabling technologies. For example, OGI partnered Ontario scientists and their international partners lead the world in the exciting arena of genomics and proteomics. Their research has implications not only for basic science, but also for areas as diverse as diabetes, autism, malaria, cancer, the environment & understanding our role in a global context. On the research programs front, we worked with Ontario’s with Ingenuity Systems to provide access to their systems Ministry of Research and Innovation to secure funding for biology software and pathway data through TCAG; and $24M targeted for Ontario-led projects, including $15M TCAG became highest volume generator in Canada of for the second phase of the Structural Genomics Consor- gene expression data sets using Affymetrix gene chips. tium (SGC) and $8.7M for six projects funded under Ge- Over the past year, more than 430 laboratories used nome Canada’s Competition III. OGI managed 18 projects TCAG’s services. This included 15% of Canadian users and platforms in the course of the past year, with total outside Ontario and 7% international users. multi-year budgets across active projects of almost $300M. To date, our portfolio includes nearly $500M worth of We have also advanced our effort -- through business projects, including both new and now completed projects. development and outreach -- to accelerate the social and economic impact of the leverageable resources gener- Ontario scientists and their international partners lead the ated by the projects we fund. Our Chair, Mark Lievonen, world in the exciting arena of genomics and proteomics. describes in his message examples of the kinds of partner- Their research has implications not only for basic science, ships that have been developed that are providing greater but also for areas as diverse as diabetes, autism, malaria, resources for research and collaboration. They demonstrate cancer, the environment and understanding our role in a a growing commitment from the private and public sectors global context. Our project portfolio published 128 papers, in this area and a better understanding of how life sciences many of which appeared in top-tier science journals, and can positively impact our country and the economy. including several discoveries appearing in Science and Na- ture that generated international excitement in, for exam- The results of our outreach activities show a greater un- ple, the areas of autism (new genes, mutations in which could derstanding and appreciation
Load more

Recommended publications
  • Universidad Autónoma De Madrid
    UNIVERSIDAD AUTÓNOMA DE MADRID DEPARTAMENTO DE BIOLOGÍA MOLECULAR Identification and functional characterization of epigenetic determinants of pancreatic CSCs Sladjana Zagorac Madrid, 2015 DEPARTAMENTO DE BIOLOGÍA MOLECULAR FACULTAD DE CIENCIAS UNIVERSIDAD AUTÓNOMA DE MADRID Identification and functional characterization of epigenetic determinants of pancreatic CSCs Sladjana Zagorac Licenciatura en Biología Molecular y Fisiología Director de Tesis: Prof. Christopher Heeschen, M.D. PhD Centro de células madre en el cáncer y el envejecimiento Barts Instituto de Cancer (BCI) This thesis, submitted for the degree of Doctor of Philosophy at the Universidad Autónoma de Madrid, has been completed in the Stem Cells & Cancer Group at the Spanish National Cancer Research Centre (CNIO) and Centre for Stem Cells in Cancer and Ageing, Barts Cancer Instutute (BCI) under the supervision of Prof. Dr. Christopher Heeschen. Dedicated to my parents, my sister Ivana and my friends who always supported me. ACKNOWLEDGEMENTS It is strange to look back in time and see myself entering true the door of CNIO my first day in Christopher’s laboratory back in October 2010. For some maybe little and for other’s so much. Thank you Christopher for replaying to my email and opening me the door of your lab! It was just a start of an incredible journey that led me where I am now, and that will mark my next trails to run. So many people I need to mention and say thanks for their unconditional help and support. Enza thank you for accepting me as your student and for being patient with me. I will never forget how you would always tell me to think why I am doing things.
    [Show full text]
  • University of Toronto University-Wide Impact Presentation
    UNIVERSITY OF TORONTO UNIVERSITY-WIDE IMPACT PRESENTATION INTRO: .......................................................................................... 2 SECTION 1: GLOBAL FOOTPRINT .............................................. 3 SECTION 2: INNOVATION AND IMPACT .................................... 15 SECTION 3: EXCELLENCE AND LEADERSHIP IN SOCIETY ..... 31 Text is not editable on animation slides. Updated May 2021 ON-SCREEN IMAGE SPEAKER’S NOTES BEGINNING OF PRESENTATION [Good afternoon]. My name is [X], and I serve as [X] at the University of Toronto. Thank you for joining us [today]. [Today] I would like to take you through a presentation that speaks to the crucial role that U of T is honoured to play in our communities and our world. U of T is a world-leading university with three campuses in the Greater Toronto Area. We provide students with a comprehensive global education, produce life-changing research, and promote economic growth and social progress in our communities. I’m going to cover three aspects: • U of T’s Global Footprint • U of T’s Innovation and Impact • U of T’s Excellence and Leadership in Society Since its very early days, U of T has been fortunate to have forged connections with institutions around the world and to have welcomed faculty and students from elsewhere to become part of the U of T community. Today, U of T’s global footprint is significant. 2 SECTION 1 GLOBAL FOOTPRINT 3 ON-SCREEN IMAGE SPEAKER’S NOTES We are immensely proud of our worldwide alumni community. Over 630,000 U of T alumni live, work and contribute to civil society in more than 190 countries and territories. Few universities in the world can rival the cultural diversity of our student population.
    [Show full text]
  • Radiation Medicine Program
    Radiation Medicine Program ANNUAL 2020 REPORT 2021 VALUES MISSION Innovation Advance exemplary radiation Excellence medicine through patient Collaboration care, research & education Accountability in partnership with CONTENTS Integrity our patients & community 4 A Message from the Chief 6 Program Overview 7 2020: The Year in Numbers 8 Strategic Roadmap to 2026 VISION 10 Clinical Care CURE EVOLVE 15 Quality & Safety Predictive Health & Precision Radiation Medicine. Advanced Particle Adaptive Radiotherapy Therapy & Theranostics 18 Education Personalized Care. 21 Research Global Impact. 26 Team RMP COMFORT & CONNECT Systems to Maximize CONFIDENCE Innovation & Wellbeing Technology-enabled Patient Experience Transformation A MESSAGE FROM THE CHIEF The Radiation Medicine Program (RMP) at the Princess Margaret Cancer Centre is committed to delivering the highest standard of patient care. Over the RMP’s innovative education programs continue to thrive and attract a diverse group of national and international attendees. Our award-winning Accelerated past year, our dynamic multidisciplinary team of radiation oncologists, medical physicists, radiation therapists, administrators, and support staff have worked Education Program (AEP) demonstrated extraordinary resourcefulness this past year, standing strong amidst the pandemic, and continuing to provide top- together to advance our vision of “Precision Radiation Medicine. Personalized Care. Global Impact.” RMP continues to uphold our foundational values of level education to a broad spectrum of learners.
    [Show full text]
  • Stem Cell Strategy by Establishing the Till & Mcculloch Medicines of Tomorrow Innovation Fund
    A Pre-Budget Submission to the House of Commons Standing Committee on Finance To Implement the Canadian Stem Cell Strategy By Establishing The Till & McCulloch Medicines of Tomorrow Innovation Fund James Price President & CEO Canadian Stem Cell Foundation February 9, 2016 EXECUTIVE SUMMARY Stem cells represent the biggest innovation in medicine of the last half century. These cells have the power to cure many diseases for which current medical practice can only provide symptomatic relief and chronic care – a reality that is straining health care systems in Canada and in countries around the globe. Stem cells are a hallmark of Canadian innovation. They were first discovered in Canada and Canada is one of the top three countries in stem cell R&D, with our scientists ranking among the best in the world. Recent investments, such as the Government’s $20-million commitment to establish a cell-manufacturing facility in Toronto and the $114-million Medicine By Design grant for the University of Toronto, will help Canada move forward. However, major commitments by competitor jurisdictions – most notably California, with its investment of $3 billion, and Japan, with an investment of $1 billion in stem cells and regenerative medicine -- challenge Canada’s leadership in this sector of the knowledge economy. Moreover, Canada lacks a national plan to succeed in the coming cell therapy and regenerative medicine boom. The Canadian Stem Cell Strategy -- created in consultation with 150 scientists, medical doctors, leaders from major health charities, industry experts, investors and philanthropists – will: • deliver up to 10 new curative therapies within 10 years; • transform health care and ease the strain on the health system; and • attract private investment and generate 12,000 jobs for Canadians.
    [Show full text]
  • Structural Genomics in North America
    © 2000 Nature America Inc. • http://structbio.nature.com perspectives Structural genomics in North America Thomas C. Terwilliger Structural genomics in North America has moved remarkably quickly from ideas to pilot projects. Just three years ago, the field was only a concept, independently being discussed by its many inventors. Now it is already a well- organized, increasingly-funded, consortium-based effort to determine protein structures on a large scale. The pivotal point for the North American folds, or proteins from fully-sequenced organisms such as yeast efforts was the 1998 Argonne meeting (see or Haemophilus influenzae that held the promise of yielding Table 1 for a timeline of structural important functional information from protein structures. genomics in North America). This meeting All the pilot projects have used more or less the same initial brought together over 80 researchers and strategy: cloning many genes and finding the ones that were high- representatives of funding agencies who ly suitable for structure determination. This process consisted of .com thought that improvements in technology, finding those genes that express well in a simple system, selecting combined with the successes of the genome from this set ones that produce protein in soluble form, testing sequencing projects, had set the stage for a large-scale structure these for crystallization or NMR spectra, and determining the determination project. Experts in all the required steps, from structures of the ones that pass all these tests. All of the projects protein expression to X-ray and NMR structure determination, have found that this process leads to a huge attrition rate at each described recent progress and how the obstacles remaining in step, with three-dimensional structures obtained for just 5–20% their areas could be overcome.
    [Show full text]
  • By the Numbers Excellence, Innovation, Leadership: Research at the University of Toronto a Powerful Partnership
    BY THE NUMBERS EXCELLENCE, INNOVATION, LEADERSHIP: RESEARCH AT THE UNIVERSITY OF TORONTO A POWERFUL PARTNERSHIP The combination of U of T and the 10 partner hospitals affiliated with the university creates one of the world’s largest and most innovative health research forces. More than 1,900 researchers and over 4,000 graduate students and postdoctoral fellows pursue the next vital steps in every area of health research imaginable. UNIVERSITY OF TORONTO Sunnybrook Health St. Michaelʼs Sciences Centre Hospital Womenʼs College Bloorview Kids Hospital Rehab A POWERFUL PARTNERSHIP Baycrest Mount Sinai Hospital The Hospital University Health for Sick Children Network* Centre for Toronto Addiction and Rehabilitation Mental Health Institute *Composed of Toronto General, Toronto Western and Princess Margaret Hospitals 1 UNIVERSITY OF TORONTO FACULTY EXCELLENCE U of T researchers consistently win more prestigious awards than any other Canadian university. See the end of this booklet for a detailed list of awards and honours received by our faculty in the last three years. Faculty Honours (1980-2009) University of Toronto compared to awards held at other Canadian universities International American Academy of Arts & Sciences* Gairdner International Award Guggenheim Fellows National Academies** Royal Society Fellows Sloan Research Fellows American Association for the Advancement of Science* ISI Highly-Cited Researchers*** 0 20 40 60 801 00 Percentage National Steacie Prize Molson Prize Federal Granting Councilsʼ Highest Awards**** Killam Prize Steacie
    [Show full text]
  • Printable List of Laureates
    Laureates of the Canadian Medical Hall of Fame A E Maude Abbott MD* (1994) Connie J. Eaves PhD (2019) Albert Aguayo MD(2011) John Evans MD* (2000) Oswald Avery MD (2004) F B Ray Farquharson MD* (1998) Elizabeth Bagshaw MD* (2007) Hon. Sylvia Fedoruk MA* (2009) Sir Frederick Banting MD* (1994) William Feindel MD PhD* (2003) Henry Barnett MD* (1995) B. Brett Finlay PhD (2018) Murray Barr MD* (1998) C. Miller Fisher MD* (1998) Charles Beer PhD* (1997) James FitzGerald MD PhD* (2004) Bernard Belleau PhD* (2000) Claude Fortier MD* (1998) Philip B. Berger MD (2018) Terry Fox* (2012) Michel G. Bergeron MD (2017) Armand Frappier MD* (2012) Alan Bernstein PhD (2015) Clarke Fraser MD PhD* (2012) Charles H. Best MD PhD* (1994) Henry Friesen MD (2001) Norman Bethune MD* (1998) John Bienenstock MD (2011) G Wilfred G. Bigelow MD* (1997) William Gallie MD* (2001) Michael Bliss PhD* (2016) Jacques Genest MD* (1994) Roberta Bondar MD PhD (1998) Gustave Gingras MD* (1998) John Bradley MD* (2001) Phil Gold MD PhD (2010) Henri Breault MD* (1997) Richard G. Goldbloom MD (2017) G. Malcolm Brown PhD* (2000) Jean Gray MD (2020) John Symonds Lyon Browne MD PhD* (1994) Wilfred Grenfell MD* (1997) Alan Burton PhD* (2010) Gordon Guyatt MD (2016) C H G. Brock Chisholm MD (2019) Vladimir Hachinski MD (2018) Harvey Max Chochnov, MD PhD (2020) Antoine Hakim MD PhD (2013) Bruce Chown MD* (1995) Justice Emmett Hall* (2017) Michel Chrétien MD (2017) Judith G. Hall MD (2015) William A. Cochrane MD* (2010) Michael R. Hayden MD PhD (2017) May Cohen MD (2016) Donald O.
    [Show full text]
  • Annual Summary Corporate Plan 2010
    THE GAIRDNER FOUNDATION Annual Summary Corporate Plan 2010 1 TABLE OF CONTENTS PAGE Section I About the Gairdner Foundation 4 Objectives and Achievements to Date 8 Economic Benefits 9 Section II Performance Results for 2009 Activities 10 Detailed 2009 Evaluations 11-14 Planned Activities and Anticipated Results 2010 15 Section III Financial Summary 16 Planned Receipts and Disbursements 2010 18 Section IV Risk Management 19 Section V Performance Monitoring 21 2 "Receiving the Gairdner Award is not only a tremendous honor. It is also an induction into the Gairdner family of exceptional biomedical scientists. The 50th anniversary celebration was a joyous family reunion." Gairdner (1981) and Nobel Laureate, Michael Brown, Southwestern University, Dallas 3 THE GAIRDNER FOUNDATION CORPORATE PLAN EXECUTIVE SUMMARY HISTORY The Gairdner Foundation was created in 1957 by James Arthur Gairdner to recognize and reward the achievements of medical researchers whose work contributes significantly to improving the quality of human life. Since the first awards were made in 1959, the Gairdner Awards have become Canada's foremost international award. The Canada Gairdner International Awards are one of the three most prestigious awards in medical science, along with the Swedish Nobel Prize in Medicine and the American Albert Lasker Medical Research Awards. They hold up the pinnacle of achievement as a mirror to Canadians, and in so doing, play a role in helping Canada achieve its goals of excellence. The Gairdner was incorporated in December 1957 as a charitable corporation under the laws of the Province of Ontario, Canada. Its funds originally derived from the personal gifts of the founder and members of his family.
    [Show full text]
  • 2011/2012 Annual Report
    BUILDINGALEGACY Stem Cell Network 2011-2012 Annual Report StemCell Network 2011-2012 Annual Report TABLE OF CONTENTS Directors’ Message .........................................................................................2 Bridging The Translational Gap ...................................................................4 In Profile: Dr. Denis-Claude Roy .............................................7 The High-Throughput Revolution................................................................8 In Profile: Dr. Aaron Schimmer .........................................11 See The Potential: An Industry-Academia Hybrid ...............................12 In Profile: Dr. Corinne Hoesli ..............................................14 A Research Conference Built by the Community .................................15 In Profile: Dr. Peter Zandstra .............................................17 Building an Informed Public.......................................................................18 In Profile: Angela McDonald .............................................21 Network Community ...................................................................................22 2011-12 Financial Statements ...................................................................25 Directors’ Message Message from SCN’s Board Chair, Scientific Director, and Executive Director t’s year 12. On paper, the Stem Cell Network has entered its for blood cancers at the University of Montréal. Dr. Roy’s project, sunset years, but we’re not ready to rest on our laurels
    [Show full text]
  • 100 Years of Biochemistry at the University of Toronto – Marian A
    Bulletin The Canadian Society of Biochemistry, Molecular & Cellular Biology La Société canadienne de biochemie, de biologie moléculaire et cellulaire ISSN 1197-6578/2007 2007 www.csbmcb.ca Bulletin The Canadian Society of Biochemistry, Molecular & Cellular Biology La Société canadienne de biochemie, de biologie moléculaire et cellulaire 2007 www.csbmcb.ca 2 CSMCB/SCBBMC BULLETIN 2007 FRONT COVER IMAGES: Illustration by Martin Krzywinski, Scientist (Mapping), Canada’s Michael Smith Genome Sciences Centre CSMCB/SCBBMC BULLETIN 2007 3 Contents CSBMCB Board for 2007-2008................................................................................................4 CSBMCB President’s Report...................................................................................................5 Incoming Members of the CSBMCB Executive Board 2006-2007....................................8 Laura Frost, Vice-President; Jean-Pierre Perreault, Councillor; David Williams, Councillor Minutes of the 50th CSBMCB Annual General Meeting ..................................................12 CSBMCB/SCBBMC Financial Statement.............................................................................15 The 50th Annual Meeting of the CSBMCB.........................................................................17 Poster and travel award recipients for the 2007 CSBMCB Meeting .............................19 Scenes from the 2007 CSBMCB Meeting ............................................................................21 Program for the 51st Annual Meeting of the
    [Show full text]
  • Biochemistry Seminars 2004
    Biochemistry Seminars 2004 Tuesday, August 31, 2004 @ 2:00 pm - MSB 341 Dr. Jacques Baudier, Visiting Professor, INSERM E0104, Grenoble, France "Nuclear S100B protein and olidodendrocyte progenitor cells differentiation" Host: Dr. Gary Shaw Friday, Sept 17, 2004 Dr. Naihe Jing, Assistant Director, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, and a Visiting Professor at Toronto's Sunny Brook Hospital until October "FGF signaling and P19 cell neural differentiation" Host: Dr. Shawn Li Friday, Sept 24, 2004 Dr. Paola Marignani, Assistant Professor, Dalhousie University "The multi-tasking tumour suppressor kinase LKB1" Host: Dr. David Litchfield Monday, September 27, 2004 @ 2:00 pm - MSB 148 Dr. Aled Edwards, Senior Scientist, Division of Molecular and Structural Biology, Toronto General Research Institute, Toronto General Hospital "Large scale protein science" Host: Steven Beasley Friday, October 1, 2004 Dr. John Lytton, Professor & Graduate Program Coordinator, Department of Biochemistry & Molecular Biology, University of Calgary Health Sciences Centre "K-dependent Na/Ca exchangers in the brain" Host: Dr. Chris Brandl Friday, October 8, 2004 Dr. Grant Brown, Associate Professor, Department of Biochemistry University of Toronto "Identifying Suppressors of Genome Instability using Functional Genomics in Yeast" Host: Dr. Megan Davey Friday, November 12, 2004 Dr. Eric Brown, Canada Research Chair in Microbial Biochemistry at McMaster University and Director of the McMaster High Throughput Screening Laboratory "Wall teichoic acids in Gram-positive bacteria: polymers that matter" Host: Dr. David Litchfield Biochemistry Biochemistry Seminars 2004 Friday, November 19, 2004 Dr. Rachel Klevit, Professor of Biochemistry and director of the Interdisciplinary Graduate Program in Biomolecular Structure and Design, University of Washington, Seattle, Washington "Assembly, Structure, & Function of the BRCA1 Ubiquitin Ligase Complex" Host: Dr.
    [Show full text]
  • CSHL AR 1977.Pdf
    ANNUAL REPORT 1977 COLD SPRING HARBOR, NEW YORK COLD SPRING HARBOR LABORATORY COLD SPRING HARBOR, LONG ISLAND, NEW YORK OFFICERS OF THE CORPORATION Dr. Harry Eagle, Chairman Edward Pulling, Vice-Chairman Dr. Bayard Clarkson, Secretary Clarence E. Galston, Treasurer William R. Udry, Assistant Secretary-Treasurer Dr. James D. Watson, Laboratory Director William R. Udry, Administrative Director BOARD OF TRUSTEES Institutional Trustees State University of New York at Stony Brook Albert Einstein College of Medicine Dr. Joseph R. Kates Dr. Harry Eagle University of Wisconsin Columbia University Dr. Julian Davies Dr. Charles R. Cantor Wawepex Society Duke University Bache Bleecker Dr. Walter Guild Harvard University Individual Trustees School of Public Health Dr. Howard Hiatt Emilio G. Collado Long Island Biological Association Robert L. Cummings Norris Darrell Edward Pulling Walter N. Frank, Jr. Massachusetts Institute of Technology Clarence E. Galston Dr. Herman Eisen William R. Grant New York University Medical Center Mrs. Robert H. P. Olney Dr. Vittorio Defendi Walter H. Page William S. Robertson Princeton University Mrs. Franz Schneider Dr. Arnold J. Levine Dr. James D. Watson The Rockefeller University Dr. Rollin Hotchkiss Honorary trustees Sloan-Kettering Institute Dr. Alexander Hollaender Dr. Bayard Clarkson Dr. H. Bentley Glass Officers and trustees listed are as of December 31,1977. DIRECTOR'S REPORT When I was a boy in Chicago, the scientist was a poorlyabout that we are closet big businessmen who need to paid, absent-minded dreamer, very bright,if not abe kept in check by massive regulations, if not the threat genius, and culturally destined never to lead the masses, of jail.
    [Show full text]